“In accordance with Decree 07/2022, VietNam now requires C and D medical device applications be submitted in CSDT format with a Vietnamese IFU.”

David Vo
General Manager
Asia Actual VietNam

Come grow with us in the US in Thailand in China in Korea in the Philippines in Taiwan in Hong Kong

Sources and Links

VietNam’s MoH Updates Class C and D Application Requirements

Published on: February 29th, 2024

Vietnam’s application requirements have been changed. Per Decree 07/2022, the application requirements for all new Class C and D applications submitted to the Vietnamese Ministry of Health (MoH) will need to be in ASEAN Common Submission Dossier Template (CSDT) format, with the addition of a Vietnamese IFU. Furthermore, the regulation states that the CSDT documents won’t need to be reviewed if the product has been approved by a Reference country and can provide the Certificate of Free Sale (CFS), or an equivalent. CSDT documentation not approved in a Reference country will be reviewed by a designated evaluation organization and will require additional time to be approved. Labeling will also need to be in Vietnamese which a local partner, like Asia Actual, can easily assist with.

Application Requirements and Update to the Review Process

As outlined in the primary medical device regulations, Decree 07/2022, Class C and D applications should be submitted in CSDT format beginning January 1, 2024. This represents a shift from the previous requirements where a more limited list of documents was required to be submitted. However, these changes should make submission easier for manufacturers that have already compiled their CSDT documentation. That being said, the Vietnamese MoH does still require the IFU be translated to Vietnamese.

While both scenarios will still need to wait in the currently very long line of applications, products with CSDT and a CFS/CFG from a Reference country can be expected to be approved quickly. The two application scenarios currently available are as follows:

  1. Exemption from Evaluation: Products approved by at least 1 Reference country, including the US (FDA), Australia (TGA), Canada, Japan, EU members, England, Switzerland, China (NMPA), and Korea (MFDS), are exempt from CSDT evaluation. Here, the MoH recognizes the credibility of evaluations conducted by these reputable regulatory bodies.
  2. CSDT Evaluation Requirement: For products without pre-existing approvals from the specified reference countries, the CSDT documentation must undergo evaluation before submission. This ensures a thorough and standardized assessment of the clinical data supporting the medical device application.

To date, the MoH has only released draft CSDT guidance which can be found here. Manufacturers and their local partners should monitor new guidance to ensure applications are submitted in accordance with the latest guidance. Asia Actual will update this article as more relevant guidance is released.

Appointment of Evaluation Organizations

The Ministry of Health, through Decision 04/QD-BYT issued on January 2, 2024, has appointed two key organizations for evaluating CSDT applications that are not already approved by a Reference country:

  1. Non-IVD Medical Devices: The Institute of Medical Device and Constructions is designated as the evaluating body. Manufacturers can find more information on their official website: nimec.gov.vn
  2. IVD Medical Devices: The National Institute for Control of Vaccine & Biological is tasked with evaluating In Vitro Diagnostic (IVD) medical devices. Further details can be obtained from their website: nicvb.org.vn

While the issuance of Decision 04/QD-BYT marks a significant step, it does not provide specific details regarding the evaluation process, timeline, or associated costs for CSDT evaluations. Stakeholders will need to await further guidance from the Ministry of Health to navigate this crucial aspect of the regulatory process.

In regard to CSDT content, Vietnam MOH have not issued official guidance for CSDT yet. We just have draft version until now (pdf). Will keep you posted.

Come Grow With Us

Asia Actual specializes in helping medical device manufacturers grow their sales in Asia with experienced, bi-lingual commercial and regulatory experts on the ground in each market.

Contact Asia Actual today with any questions on how Decree 07/2022 may affect your business.

Blog Posts

Australia SaMD Transition Deadline

Australia’s SaMD Regulatory Deadline

Beginning on November 1st, 2024, Australia's Therapeutic Goods Administration will implement new rules surrounding software as a medical device (SaMD). While some SaMD will require additional regulatory requirements, other SaMD will be exempted from some, or excluded completely, from the new regulations.
Thai FDA Documentation Exemptions for Concise and Full Regulatory Pathways

Thai FDA Regulatory Documentation Exemptions

March 12, 2024: the Thai FDA released draft guidance updating the list of required documentation for Full and Concise Evaluation. For manufacturers registering a medical device in Thailand, certain documents are no longer required.
Hong Kong MDD adds Singapore HSA to Reference Country List

Hong Kong MDD Adds Singapore as Reference Country

Starting April 2nd, 2024, the Hong Kong Medical Device Division (MDD) accepts, on a regular basis, the marketing approvals obtained from the the Health Sciences Authority (HSA) of Singapore as a support of compliance of medical device to the "Essential Principles of Safety and Performance of Medical Devices" (Technical Reference: TR-004) under MDACS.